📲 Install as app Add Insight Labs to your home screen — daily brief, one tap away.

Add Insight Labs to your home screen

Get the daily brief like an app — one tap, no browser bar, works offline.

  1. Tap the button at the bottom of Safari
  2. Scroll and tap Add to Home Screen
  3. Tap Add in the top right — done

Works on iPhone & iPad. The icon will appear like any app.

Edition #190

The Insight Labs Daily.

Sun · Jul 19 · 2026 ~7 min read
★ Lead Story
2 days ago · 2 min read

Wegovy cleared for fatty liver

India's drug regulator approved Novo Nordisk's semaglutide, sold here as Wegovy, for metabolic fatty liver disease on 17 July. Until this week the same molecule had one mainstream Indian use: weight loss.

That distinction matters more than it sounds. A weight-loss prescription is discretionary spending. A liver-disease prescription is treatment for a condition with a diagnosis, a specialist, and a reason to keep taking the drug after the scale stops moving.

Fatty liver is not a niche condition in India. Hepatology surveys have put non-alcoholic fatty liver disease at close to a third of Indian adults, sitting alongside the diabetes and cardiac load the country already carries.

Novo Nordisk and Eli Lilly have spent eighteen months building an Indian GLP-1 market on aesthetics and metro pharmacy demand. This approval moves the product one shelf across, into chronic care.

The question is whether the prescribing base moves with it, or whether the drug stays where its price has kept it.

The commercial argument for a therapeutic indication is duration. Weight-loss users churn: they stop when they hit a target, when the cost bites, or when side effects outlast motivation. Chronic liver patients are managed for years, and adherence becomes a clinical instruction rather than a personal choice.

It also changes who is allowed to write the prescription. Hepatologists and gastroenterologists now have a labelled reason to use a drug that was largely being handled by endocrinologists and aesthetic clinics. That widens the funnel without any additional marketing spend.

The constraint is price. At current Indian pricing, GLP-1 therapy costs more per month than most private policies reimburse for outpatient drugs, and fatty liver disease is concentrated well below the income band that has been buying Wegovy so far. An approval expands who could be treated; it does not by itself expand who can afford to be.

Today's Top 5

5 stories
Netflix · 2 days ago

Netflix stops showing its homework

Netflix beat estimates on 17 July with revenue up about 13%, then lost close to a tenth of its market value in a day. The forecast for the coming quarter came in soft, and the company said it will report less viewership data going forward.

Price increases and the ad-supported tier did most of the revenue work this quarter. Both are levers you can pull once. Neither tells an investor how many people actually watched anything.

Cutting back on viewership disclosure at the same moment growth slows is a choice about what the market is allowed to measure.

The ad tier is the part that needs the numbers most. Advertisers price inventory on reach, and the less Netflix publishes about what gets watched, the more it is asking buyers to take the audience on trust while the ad business is still being built.

For India this cuts a specific way. The market has been sold to global streamers as subscriber upside, and the reporting shift makes Indian traction harder to verify from outside. Local players who do disclose reach may find that transparency is worth something in the ad market.

IAMAI · 2 days ago

E-commerce gets one lobby desk

IAMAI launched the E-Commerce Council of India on 17 July, pulling marketplaces, brands, logistics firms, payment providers, exporters and MSMEs into a single body for a sector it sizes at $120 billion.

Indian digital commerce has been arguing with itself in public for years: marketplaces against sellers, quick commerce against kirana associations, D2C brands against platform fees. Regulators have been reading contradictory submissions from the same industry.

A unified council is an attempt to arrive at policy conversations with one position instead of six.

The harder part is that the members' interests genuinely diverge. A dark-store operator and a small-town seller do not want the same rules on inventory, discounting or data. Consolidating them into one voice usually means the largest members set the position.

Watch which issues the council picks first. If it opens with logistics and export facilitation, it is a trade body. If it opens with platform-fee norms or FDI in inventory-led retail, it is something with more weight behind it.

Transport · 1 day ago

Maharashtra buses cost 13% more

Maharashtra raised state bus fares by more than 13% from 18 July, citing diesel prices. The earlier 10% seasonal surcharge on ordinary buses was withdrawn at the same time.

State transport is the cheapest intercity option for households that do not own a vehicle, which is most of the state outside the metros. A fare revision here lands on daily commuters and small-town traders, not on discretionary travel.

It is also a reading on how fuel costs are travelling through the economy. Companies absorbed diesel for two quarters. Public transport has stopped absorbing it.

Fuel-linked fare rises tend to be sticky. When diesel eases, transport corporations rarely reverse the increase in full, because the same costs sit in wages, maintenance and depreciation that never went down.

For consumer companies selling into interior Maharashtra, this is a quiet drag. Every rupee added to a monthly commute is a rupee that does not reach a shelf, and it lands in the same quarter that rural incomes are already dealing with a shaky sowing season.

Bharat Tex · 2 days ago

Textiles booked ₹14,300 crore

Bharat Tex closed with about $2 billion in buyer enquiries and roughly ₹14,300 crore in investment commitments across more than 30 MoUs, organisers said on 17 July.

Enquiries are not orders and MoUs are not factories. The number worth watching is the investment commitment, because textiles is the rare sector where India's labour cost advantage still translates directly into capacity.

The competitive set has shifted. Bangladesh's political disruption and China's cost inflation have both loosened, and buyers are looking for a third source rather than a replacement.

Where the commitments land will matter more than their size. Indian textile capacity has historically clustered in Tiruppur, Surat and Ludhiana, and adding to existing clusters is faster but does little for the state-level incentives these MoUs are usually written against.

The gap in India's chain remains man-made fibre. Global demand has moved toward synthetics while India's strength stayed in cotton, and no volume of buyer enquiries fixes a raw-material mismatch that takes petrochemical investment to close.

Apple · 2 days ago

Apple retakes the top spot

Apple passed Nvidia on 17 July to become the world's most valuable company again, at about $4.88 trillion against $4.86 trillion. The same session saw the chip index slide into bear-market territory after a 105% run.

The rotation is from AI infrastructure toward AI monetisation. Selling the shovels was the trade for two years; the market is now asking who charges the end customer.

Apple's claim is that it owns the device the customer already pays for. That is a distribution argument, not a technology one.

For Indian IT services, the shift is more favourable than the headline suggests. A market that stops paying for compute capacity and starts paying for deployed outcomes is a market that needs implementation partners, which is what the Indian majors sell.

The risk is timing. Infrastructure spending falls faster than services demand rises, and companies that budgeted for AI capex often cut the pilot projects first. A rotation on Wall Street can still show up as a slow quarter in Bengaluru.

⚡ 30-Second Scan

Snapdeal has a Supreme Court notice over Karnataka's plea on the online sale of a prescription drug without a prescription — an early test of platform liability for pharmacy listings.
SEBI issued an advisory on the 'Boss Scam' after an alert from the Indian Cyber Crime Coordination Centre, covering impersonation of senior executives to authorise transfers.
HCLTech opened a technology centre in GIFT City with 500 engineers, built to serve global financial-services clients from an Indian regulatory zone.

Sourced from public reporting; analysis by The Insight Labs.

Sources: The Hindu BusinessLine, NDTV Profit, Economic Times.

Want the Tuesday deep-dive?

The Insight Labs newsletter · every Tuesday · one full FMCG case-study from inside the P&L. Free.

Subscribe →
Today's edition · ~8 min read